vs
Side-by-side financial comparison of DYNEX CAPITAL INC (DX) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $43.5M, roughly 1.3× DYNEX CAPITAL INC). On growth, DYNEX CAPITAL INC posted the faster year-over-year revenue change (531.3% vs 36.9%). Over the past eight quarters, DYNEX CAPITAL INC's revenue compounded faster (75.8% CAGR vs 48.5%).
Dynex Capital Inc. is a publicly traded real estate investment trust headquartered in the United States. It specializes in investing in and managing a diversified portfolio of mortgage-backed securities, residential and commercial mortgage loans, and other mortgage-related assets. It delivers consistent returns to shareholders via regular dividends and long-term capital growth.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
DX vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $43.5M | $57.3M |
| Net Profit | — | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | — | -82.2% |
| Net Margin | — | -83.0% |
| Revenue YoY | 531.3% | 36.9% |
| Net Profit YoY | — | -9.6% |
| EPS (diluted) | $1.59 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $43.5M | $57.3M | ||
| Q3 25 | $30.6M | $51.3M | ||
| Q2 25 | $23.1M | $48.5M | ||
| Q1 25 | $17.1M | $32.7M | ||
| Q4 24 | — | $41.8M | ||
| Q3 24 | — | $33.3M | ||
| Q2 24 | — | $29.1M | ||
| Q1 24 | $-3.2M | $26.0M |
| Q4 25 | — | $-47.5M | ||
| Q3 25 | $150.4M | $-52.9M | ||
| Q2 25 | $-13.6M | $-46.6M | ||
| Q1 25 | $-3.1M | $-49.5M | ||
| Q4 24 | — | $-43.3M | ||
| Q3 24 | — | $-43.6M | ||
| Q2 24 | — | $-32.3M | ||
| Q1 24 | $40.1M | $-141.4M |
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | — | -82.2% | ||
| Q3 25 | — | -102.6% | ||
| Q2 25 | — | -93.4% | ||
| Q1 25 | — | -143.7% | ||
| Q4 24 | — | -98.6% | ||
| Q3 24 | — | -132.0% | ||
| Q2 24 | — | -139.2% | ||
| Q1 24 | — | -538.7% |
| Q4 25 | — | -83.0% | ||
| Q3 25 | 491.3% | -103.1% | ||
| Q2 25 | -58.8% | -96.1% | ||
| Q1 25 | -18.0% | -151.4% | ||
| Q4 24 | — | -103.6% | ||
| Q3 24 | — | -131.2% | ||
| Q2 24 | — | -110.9% | ||
| Q1 24 | -1256.8% | -544.4% |
| Q4 25 | $1.59 | $-0.73 | ||
| Q3 25 | $1.08 | $-0.82 | ||
| Q2 25 | $-0.14 | $-0.75 | ||
| Q1 25 | $-0.06 | $-0.81 | ||
| Q4 24 | — | $-0.71 | ||
| Q3 24 | — | $-0.73 | ||
| Q2 24 | — | $-0.55 | ||
| Q1 24 | $0.64 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $531.0M | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.5B | $139.1M |
| Total Assets | $17.3B | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $531.0M | $388.9M | ||
| Q3 25 | $491.0M | $416.1M | ||
| Q2 25 | $387.5M | $291.0M | ||
| Q1 25 | $327.4M | $314.5M | ||
| Q4 24 | — | $320.6M | ||
| Q3 24 | — | $298.4M | ||
| Q2 24 | — | $319.1M | ||
| Q1 24 | $295.7M | $201.2M |
| Q4 25 | $2.5B | $139.1M | ||
| Q3 25 | $2.0B | $148.8M | ||
| Q2 25 | $1.6B | $-11.9M | ||
| Q1 25 | $1.4B | $18.9M | ||
| Q4 24 | — | $21.7M | ||
| Q3 24 | — | $11.2M | ||
| Q2 24 | — | $39.3M | ||
| Q1 24 | $958.5M | $61.6M |
| Q4 25 | $17.3B | $480.2M | ||
| Q3 25 | $14.2B | $506.9M | ||
| Q2 25 | $11.3B | $372.7M | ||
| Q1 25 | $9.0B | $386.7M | ||
| Q4 24 | — | $392.3M | ||
| Q3 24 | — | $363.6M | ||
| Q2 24 | — | $381.8M | ||
| Q1 24 | $6.3B | $258.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $120.8M | $-25.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $120.8M | $-25.4M | ||
| Q3 25 | $68.3M | $-26.6M | ||
| Q2 25 | $31.9M | $-23.3M | ||
| Q1 25 | $6.4M | $-40.4M | ||
| Q4 24 | — | $-18.8M | ||
| Q3 24 | — | $-25.2M | ||
| Q2 24 | — | $-29.1M | ||
| Q1 24 | $-17.1M | $-40.7M |
| Q4 25 | — | — | ||
| Q3 25 | 0.45× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.43× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
